What Chorulon Treats: Main Uses and Benefits

Chorulon is a treatment option that may help address specific reproductive conditions in animals where hormonal imbalance is a contributing factor. It may be used to support the management of certain clinical scenarios, including follicular cysts, anestrus, and cryptorchidism.

The medication offers a method to potentially assist in the re-establishment of expected reproductive cycles and support the return to a stable physiological state. The goal of using this treatment is to help manage symptoms associated with these specific conditions and to support normal function, rather than guaranteeing a specific clinical outcome. This information is consistent with regulatory standards for veterinary medicines.

Quick Fact: Relief for Hormonal Imbalances

This section outlines the official population eligibility and exclusions for the veterinary medicine, Chorulon, as defined by authoritative regulatory documents.

Eligibility Scope

Classification	Population/Condition
Allowed Populations	Specific animal species, including Cows and Brood Finfish, for the officially labeled reproductive conditions (e.g., cystic ovaries, spawning aid).
Contraindicated Groups	Animals with a documented history of hypersensitivity or allergy to the active substance, Chorionic Gonadotrophin, or any of its excipients.
Use Restriction	Use is restricted to being by or on the order of a licensed veterinarian (Prescription status).

Specific Limitations

Eligibility is implicitly restricted to sexually mature animals due to the drug’s intended reproductive function; no explicit age-based limits for young or older animals are documented. Some regulatory labels state the medicine must not be used during pregnancy. Usage is generally permitted in lactating cows, with no required withdrawal period for milk or meat.

Furthermore, for food-producing finfish, use is subject to a maximum total dose restriction. The official veterinary prescribing information lists no specific contraindications based on renal or hepatic impairment.

Interactions with other medicines and products

The official regulatory documentation detailing the use of Chorulon (Chorionic Gonadotrophin) establishes a distinct interaction profile characterized primarily by the absence of known systemic drug-drug effects. This profile is consistent with the nature of the active ingredient, a protein hormone, which typically does not participate in the common metabolic or transport pathways associated with pharmacokinetic interactions.

Systemic Drug-Drug and Substance Interactions

Regulatory summaries explicitly state that no systemic interactions with other medicinal products are known. This classification applies to potential pharmacokinetic interactions (such as those affecting exposure or clearance) and pharmacodynamic interactions (such as additive or opposing effects). Furthermore, no interactions with food, alcohol, or herbal products are documented in the official labeling for this veterinary medicine.

Product Incompatibility

A formal restriction is classified as Major Incompatibility. Official documents mandate that the final reconstituted Chorulon solution must not be mixed with any other veterinary medicinal product, other than the solvent supplied for its reconstitution. This restriction ensures product integrity and adherence to approved administration protocols.

Interference with Diagnostic Procedures

The presence of Chorionic Gonadotrophin may cause a procedural interaction by interfering with certain laboratory assays. The hormone may lead to unreliable results in radioimmunoassay tests used to measure other natural gonadotrophins, such as Luteinizing Hormone (LH).

How Chorulon Works: Mechanism of Action

Chorulon is a preparation containing Human Chorionic Gonadotropin (hCG), an alpha and beta heterodimeric glycoprotein that functions as an agonist at the Luteinizing Hormone (LH) receptor. This receptor is primarily expressed on the surface of ovarian thecal cells and testicular Leydig cells.

Binding of Chorulon to the LH receptor activates a classic G-protein coupled receptor (GPCR) signaling pathway. This interaction stimulates the G-alpha-s subunit, which, in turn, activates adenylyl cyclase. This enzyme catalyzes the conversion of ATP to the second messenger, cyclic adenosine monophosphate (cAMP).

The resultant increase in intracellular cAMP levels activates protein kinase A (PKA). Activated PKA subsequently phosphorylates key regulatory proteins, driving the transcription and activity of enzymes crucial for the biosynthesis of steroid hormones, a process termed steroidogenesis. Specifically, this modulates the function of the hypothalamic-pituitary-gonadal (HPG) axis by directly stimulating the production and secretion of testosterone by Leydig cells and progesterone and estrogens by the corpus luteum.

Chorulon's administration is governed by specific preparation requirements and precise, species-dependent dosages outlined in regulatory documentation. The product is supplied as a freeze-dried powder and must undergo reconstitution with the accompanying sterile solvent immediately prior to use.

---

Administration Route and Preparation Protocol

Administration is strictly parenteral, performed through either intramuscular (I.M.) or intravenous (I.V.) injection, observing aseptic precautions. The preparation of the powder and solvent must be carried out immediately before the dose is needed. The resulting solution is time-sensitive: it must be administered right away or, if stored refrigerated (2 C to 8 C), must be discarded after 24 hours. The reconstituted solution is not intended for long-term storage or future use.

---

Official Dosing and Scheduling

The official dosing schedules are highly individualized by target animal species and specific clinical scenario, as detailed in product labeling. Dosages are expressed in International Units (IU) and follow distinct frequency patterns:

Target Species / Condition	Administration Route	Typical Dosing Regimen (IU)	Frequency/Duration Pattern
Cows (Cystic Ovaries)	I.M. or I.V.	3,000 IU (I.V.) or 10,000 IU (I.M.)	Single dose; may be repeated in 14–21 days.
Cows (Conception Failure)	I.M. or I.V.	1,500 IU	Single dose at time of A.I. or mating.
Male Dogs (Libido/Cryptorchidism)	I.M.	100–500 IU	Twice weekly for up to 6 weeks.

This instruction set defines the use of Chorulon as a parenteral treatment administered according to a time-sensitive preparation protocol and finite, species-specific regimens, which are strictly described in regulatory documents.

Research Evidence / Overview of Studies for Chorulon

---

Evidence for Managing Ovarian Cysts and Cycles in Cattle

Research has studied Chorulon for use in cows with specific reproductive issues, such as ovarian cysts that cause conditions like nymphomania (constant or frequent heat) or anoestrus (absence of heat). The core evidence was observed in Randomized Controlled Trials (RCTs) and controlled field studies, which form the basis of the research summary. These studies research examined different protocols, often including comparisons to other hormonal agents like GnRH within the study design.

The studies research examined several key factors, including ovarian responses, hormonal biomarker shifts (specifically progesterone), and time-to-event measures like the interval until the cow returned to a regular reproductive cycle. Studies measured the luteinization of existing cystic follicles following administration. The studies monitored outcomes such as the rate of return to estrus and subsequent conception rates, which were tracked up to 70–100 days post-treatment.

What remains uncertain is the consistency of results across all published studies, particularly regarding long-term reproductive outcomes such as cumulative pregnancy rates. The evidence may be influenced by the cow's post-partum status or the specific type of cyst present at the time of research.

---

Evidence for Fertility Support in Subfertile Cattle

Chorulon was evaluated in studies focusing on fertility support. The core study population consisted of lactating dairy cows categorized as "repeat breeders" in research that studied the effectiveness of the hormone—those that have not conceived after multiple breeding attempts. This research primarily utilized RCTs and synthesis through meta-analyses to compare the hormone's use against non-treatment or other standard protocols.

The research highlights a particular limitation: the relationship between administration timing and outcome measurements appears to be associated with the specific breeding protocol. Furthermore, the evidence is limited in providing a definitive understanding of its effect across all fertility levels, and inconsistent results were observed when comparing different large-scale trials.

---

Evidence in Different Species and Special Populations

Research has also studied this hormone in different species. For mares, studies included populations in estrus with a large ovarian follicle, where time to ovulation was monitored. The research describes that the observations were variable depending on the mare's reproductive season.

For male dogs with cryptorchidism (undescended testicles), evidence was observed in some studies that monitored outcomes related to testicular descent, but the data quality for this specific use remains insufficient, and certainty remains low.

---

What Remains Uncertain About the Research Findings

The research highlights several key areas where evidence is limited or requires further study. Evidence quality varies across studies, and results are often complicated by the heterogeneity of the study populations. The evidence base generally provides limited information for long-term outcomes beyond immediate pregnancy or spawning events, which means the follow-up durations were limited for sustained evaluation.

Common questions about Chorulon (FAQ)

Q: Has Chorulon been approved by major regulatory bodies like the FDA or EMA?

Official documents confirm that Chorulon is authorized for use in the United States by the Food and Drug Administration (FDA) under a New Animal Drug Application (NADA). The product is also authorized in Europe, evidenced by the existence of a Summary of Product Characteristics (SmPC) issued by the EMA/VMD.

Q: Can men use Chorulon?

Chorulon is a veterinary product that is explicitly labeled “FOR ANIMAL USE ONLY.” It is approved by the U.S. Food and Drug Administration (FDA) under a New Animal Drug Application exclusively for specific animal species. This product has not been approved for use in humans.

Q: What is the official safety classification of Chorulon?

Chorulon is classified as a Prescription Animal Drug (POM-V in some regions) in official regulatory documents. Its distribution and use are restricted by law to being by or on the order of a licensed veterinarian.

Q: Is Chorulon considered a controlled substance?

According to official information, the U.S. Drug Enforcement Agency (DEA) does not classify Chorulon as a controlled substance under federal law.

Q: Is Chorulon safe to use during pregnancy or while breastfeeding?

Official labeling states that Chorulon is formally contraindicated during pregnancy. Regarding use in lactating animals, official guidelines indicate that use is generally permitted in lactating cows, with no required withdrawal period for milk or meat.

Q: Are there specific health conditions that prevent someone from using Chorulon?

Regulatory documents list two formal contraindications: a known hypersensitivity or allergy to the active ingredient, and use during pregnancy. While these conditions prevent use, official labeling does not list other specific diseases, such as renal or hepatic impairment, as formal reasons to avoid the medicine.

Q: What are the most common reported side effects of Chorulon?

Official regulatory documents only list one serious adverse reaction: anaphylaxis (a severe allergic reaction), which is classified as rare. These documents do not provide a list of common, non-serious side effects for the target animal species. For a full description of potential reactions, refer to the official 'Possible side effects and safety information' section.

Q: How quickly should someone expect to see the effects of Chorulon?

Studies summarized in official product information indicate that the active ingredient, Chorionic Gonadotrophin, is rapidly absorbed following injection. It typically reaches its peak concentration in the bloodstream of target species within eight hours. The actual time it takes to observe the desired effect can vary depending on the specific animal species and the reason for use.

Q: How long does Chorulon stay in the system after the last use?

The time the active ingredient remains in the system is described by its elimination half-life in regulatory documents. This half-life is approximately 10 hours in cattle and around 27 hours in pigs, with the exact duration varying between target species.

Q: Is the active ingredient in Chorulon the same as [similar drug name]?

The active component in Chorulon is Chorionic Gonadotrophin (hCG), which is a specific type of protein hormone. Although other commercial products may also contain this active ingredient, the final composition, excipients, and official regulatory approval of those products may differ from Chorulon.

Q: What is the difference between Chorulon and other HCG products?

Chorulon is defined by its regulatory status as a prescription veterinary medicine approved exclusively for use in specific animal species. Official documentation describes its composition as a freeze-dried preparation of chorionic gonadotropin (hCG) with a sterile diluent. This specific formulation and intended use differentiate it from human-use or non-regulated HCG products.

Q: What happens if someone uses Chorulon who should not?

The official documentation includes a safety warning advising users to take care to avoid accidental self-injection during administration. If accidental exposure occurs, official guidance indicates that immediate medical advice should be sought.

Q: Why do some people use Chorulon for non-medical reasons?

Official documentation states that Chorulon is a veterinary medicine that is restricted by federal law to use by or on the order of a licensed veterinarian. The product is strictly labeled “FOR ANIMAL USE ONLY.” Misuse of this product in humans or off-label use in animals is not sanctioned by regulatory bodies.

Q: Is Chorulon widely used in other countries outside the U.S.?

Official regulatory information confirms that Chorulon is authorized for use in the United States by the FDA and is also authorized in Europe. Its European authorization is documented by the Summary of Product Characteristics (SmPC) issued by the EMA/VMD.

Chorulon (Chorionic Gonadotrophin) must be stored under specific environmental and temperature-controlled conditions to ensure its stability, as required by regulatory labeling.

Official Storage Requirements

Product Form	Temperature Range	Protection and Container
Freeze-Dried Powder	Store in a refrigerator (2 C to 8 C).	Keep in the original container and protect from light.
Reconstituted Solution	Store in a refrigerator (2 C to 8 C).	Stable for only 24 hours. Must not be frozen.

Handling and Disposal

The product must be kept out of the sight and reach of children. The freeze-dried powder has a labeled shelf life of 3 years when stored correctly. Once reconstituted, any solution not used within 24 hours must be discarded. Disposal of unused product and waste material must be done according to local requirements and should not be placed into household waste or wastewater.